Patent · US Active

Compound and method for treating myotonic dystrophy

US8835402B2 · kind B2 · utility

78Cited by
8References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 26, 2013
Grant dateSep 16, 2014
Priority date
Expiry dateSep 26, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2810/40
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.